BriaCell to Showcase Positive Phase 3 QOL Data and Bria-OTS+ Preclinical Findings
BriaCell will present four posters at the AACR Annual Meeting, including pivotal Phase 3 Bria-IMT plus checkpoint inhibitor data showing maintained quality of life in pretreated metastatic breast cancer patients. Presentations also include preclinical Bria-OTS+ results demonstrating coordinated innate and adaptive immune activation across breast, prostate, lung and melanoma models.
1. AACR Presentation Overview
BriaCell will present four posters at the 2026 AACR Annual Meeting in San Diego, April 17–22. These include one poster on its pivotal Phase 3 Bria-IMT plus checkpoint inhibitor trial, two posters with further Phase 2 analyses and one showcasing preclinical Bria-OTS+ data.
2. Phase 3 Bria-IMT Quality of Life Data
In the pivotal Phase 3 study of Bria-IMT combined with an immune checkpoint inhibitor, heavily pretreated metastatic breast cancer patients maintained overall health status and key functional measures, indicating a favorable safety and quality of life profile for late-stage patients.
3. Bria-OTS+ Preclinical Immune Activation Findings
Preclinical studies of Bria-OTS+, a next-generation personalized off-the-shelf immunotherapy, demonstrated coordinated activation of CD4+ and CD8+ T cells, NK, NKT and B cells, increased cytokine release and persistent immune competence in breast, prostate, lung and melanoma models.